Division of Transplantation, Department of Surgery, University of Illinois at Chicago, Illinois, USA.
Curr Opin Organ Transplant. 2010 Jun;15(3):346-8. doi: 10.1097/MOT.0b013e3283398fa4.
To analyze the current status of living donor intestinal transplantation (LDIT) as a treatment option for intestinal failure.
Long-term outcomes from LDIT and combined living donor intestinal/liver transplantation (CLDILT) are comparable with those from transplantation using deceased donors. In certain life-threatening situations, especially in pediatric patients, this strategy may offer potential advantages.
According United Network for Organ Sharing (UNOS) data children with intestinal failure affected by liver disease secondary to parenteral nutrition have the highest mortality on a waiting list compared with all candidates for solid organ transplantation. Elective nature of CLDILT offers multiple advantages for this patient population. LDIT also could be life-saving option for patients with intestinal failure who run out of venous access. Optimal timing, short ischemia time and good human leukocyte antigen (HLA) matching may contribute to lower postoperative complications. Current literature suggests that living intestinal donors experience very low morbidity and high level of satisfaction.
分析作为肠衰竭治疗选择的活体供肠移植（LDIT）的现状。
LDIT 和联合活体供肠/肝移植（CLDILT）的长期结果与使用已故供者的移植结果相当。在某些危及生命的情况下，特别是在儿科患者中，这种策略可能具有潜在优势。
根据美国器官共享联合网络（UNOS）的数据，与所有实体器官移植候选者相比，因肠外营养导致肝病而患有肠衰竭的儿童在等待名单上的死亡率最高。CLDILT 的选择性为该患者群体带来了多种优势。LDIT 也可能是因静脉通路用尽而患有肠衰竭的患者的救命选择。最佳时机、短缺血时间和良好的人类白细胞抗原（HLA）匹配可能有助于降低术后并发症。目前的文献表明，活体肠供者的发病率非常低，满意度很高。
